CRIS Current Research Information System

CASTAGNETTI, FAUSTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.218
EU - Europa 5.795
AS - Asia 3.010
AF - Africa 382
SA - Sud America 28
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 5
Totale 17.450
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.203
GB - Regno Unito 1.984
CN - Cina 1.151
SE - Svezia 893
IT - Italia 771
DE - Germania 743
VN - Vietnam 650
SG - Singapore 589
IN - India 347
IE - Irlanda 248
UA - Ucraina 242
FR - Francia 226
RU - Federazione Russa 223
ZA - Sudafrica 142
EE - Estonia 136
TG - Togo 125
JP - Giappone 87
CH - Svizzera 83
JO - Giordania 81
BG - Bulgaria 79
NG - Nigeria 50
CI - Costa d'Avorio 44
BE - Belgio 40
FI - Finlandia 40
GR - Grecia 21
TR - Turchia 19
IR - Iran 18
SC - Seychelles 18
NL - Olanda 15
CA - Canada 14
BR - Brasile 12
AU - Australia 10
AT - Austria 9
HK - Hong Kong 9
LB - Libano 9
RO - Romania 9
CL - Cile 8
TW - Taiwan 8
KR - Corea 7
PL - Polonia 6
BD - Bangladesh 5
CZ - Repubblica Ceca 5
EC - Ecuador 4
ID - Indonesia 4
IL - Israele 4
PH - Filippine 4
UZ - Uzbekistan 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AE - Emirati Arabi Uniti 3
DK - Danimarca 3
IQ - Iraq 3
MY - Malesia 3
NO - Norvegia 3
PT - Portogallo 3
BO - Bolivia 2
ES - Italia 2
EU - Europa 2
LT - Lituania 2
LV - Lettonia 2
NZ - Nuova Zelanda 2
SA - Arabia Saudita 2
AL - Albania 1
AR - Argentina 1
BA - Bosnia-Erzegovina 1
EG - Egitto 1
HR - Croazia 1
HU - Ungheria 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MA - Marocco 1
ML - Mali 1
MX - Messico 1
PE - Perù 1
PK - Pakistan 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 17.450
Salva come PNG Salva come JPEG
Città #
Southend 1.849
Fairfield 1.100
Chandler 880
Ashburn 659
Woodbridge 579
Wilmington 554
Singapore 521
Houston 519
Seattle 505
Dong Ket 464
Cambridge 393
Princeton 393
Ann Arbor 326
Dublin 248
Nanjing 177
Beijing 161
Westminster 157
Padova 141
Bologna 129
Lomé 125
Jacksonville 119
Berlin 114
Santa Clara 97
New York 86
Amman 81
Sofia 79
Saint Petersburg 78
Bern 76
Jinan 75
Turin 72
Shenyang 71
Tokyo 67
San Diego 60
Nanchang 56
Milan 53
Changsha 51
Abeokuta 50
Falls Church 50
Hebei 48
Boardman 47
Abidjan 44
Medford 44
Tianjin 42
Jiaxing 41
Brussels 40
Helsinki 39
Bremen 34
Des Moines 31
Mülheim 31
Redmond 30
Florence 28
Norwalk 28
Guangzhou 26
Los Angeles 25
Zhengzhou 24
Dearborn 22
Hangzhou 22
Mountain View 21
Taizhou 21
Ningbo 20
Redwood City 19
Olalla 18
Rome 18
Shanghai 18
Mahé 16
Haikou 15
Washington 15
Chengdu 14
Frankfurt am Main 13
Kunming 13
Bühl 12
Paris 12
Taiyuan 12
London 11
Boydton 10
Istanbul 10
Kuban 10
Verona 10
Fuzhou 9
Harbin 9
Lanzhou 9
Phoenix 9
Prineville 9
San Venanzo 9
Toronto 9
Andover 8
Wuhan 8
Brescia 7
Forlì 7
Fort Worth 7
Hyderabad 7
São Paulo 7
Buffalo 6
Frankfurt Am Main 6
Shenzhen 6
Zanjan 6
Castelfranco Emilia 5
Chicago 5
Groningen 5
Las Vegas 5
Totale 12.327
Salva come PNG Salva come JPEG
Nome #
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 326
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 213
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 213
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 204
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 199
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 196
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 194
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 178
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 173
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 169
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 165
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 162
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 161
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 160
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 155
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 154
Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients 138
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 137
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 137
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 133
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 132
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 129
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL 127
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA 126
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 126
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 125
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 125
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 125
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia 123
null 122
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. 121
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison. 121
Charlson comorbidity index and adult comorbidity evaluation-27 might predict compliance and development of pleural effusions in elderly chronic myeloid leukemia patients treated with dasatinib after resistance/intolerance to imatinib. 121
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients 121
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 119
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 118
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 118
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 116
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 115
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 113
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib 112
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 112
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 112
Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables 111
Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457 110
The EUTOS population-based registry: Incidence and clinical characteristics of 2904 CML patients in 20 European Countries 110
Successful treatment of bilateral endogenous Fusarium solani endophthalmitis in a patient with acute lymphocytic leukaemia 110
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 109
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 109
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 109
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 109
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 108
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 108
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia 107
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 107
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 107
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 106
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 105
Tyrosine kinase inhibitors in chronic myeloid leukaemia: Which, when, for whom? 105
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 105
IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. 105
null 104
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study 104
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 104
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 103
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 103
null 102
One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study 102
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 102
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. 101
Leucemia mieloide cronica: terapia molecolare 101
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. 101
Diagnosis and classification of the risk 101
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview 101
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 99
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 99
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 98
High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors 97
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 97
The long-term durability of cytogenetic response in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up 96
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs) 96
A review of the European LeukemiaNet recommendations for the management of CML 95
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 95
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 95
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia 95
Explaining the in vitro and in vivo differences in leukemia therapy. 94
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. 94
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 94
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 93
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey 93
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib 92
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients 92
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib. 91
DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia 91
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 91
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 91
Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 91
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. 90
GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION 90
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 90
Totale 12.054
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.230
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.230
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.866 0 0 0 292 521 437 594 587 638 307 193 297
2020/20212.506 437 180 77 84 40 78 38 163 279 103 218 809
2021/20223.217 305 86 239 290 326 198 59 218 159 223 526 588
2022/20233.653 417 575 196 439 264 262 143 193 592 99 305 168
2023/20241.061 48 154 62 101 78 263 66 61 42 65 65 56
2024/20251.283 126 692 381 84 0 0 0 0 0 0 0 0
Totale 18.005